Physician profile
Paloma Alejandro
NPI 1578820577
$32,716.56
in general payments reported to CMS, 2019-2025
18 companies · $9,124 in 2025
The $9,124 reported for 2025 was more than what 89% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $39.75 · 2021: $1,589 · 2022: $909 · 2023: $7,731 · 2024: $13K · 2025: $9,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $3,211 · Education: $99.00 · Travel and Lodging: $56.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,437.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,375.00 |
| Food and Beverage | $3,210.89 |
| Education | $99.00 |
| Travel and Lodging | $56.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $15,994.34 | 2022-2025 | Rinvoq |
| Glaxosmithkline, LLC. | $12,277.80 | 2021-2025 | Benlysta |
| Janssen Pharmaceuticals, INC | $1,326.84 | 2021-2024 | Tremfya |
| Horizon Therapeutics Plc | $614.98 | 2021-2023 | Tepezza, Krystexxa |
| Novartis Pharmaceuticals Corporation | $419.56 | 2022-2024 | |
| Amgen INC. | $398.72 | 2021-2025 | Enbrel, Krystexxa, Evenity |
| Ucb, INC. | $293.19 | 2023-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $212.33 | 2022-2024 | Saphnelo |
| Eli Lilly Export S.A. Puerto Rico Branch | $207.75 | 2020-2025 | Taltz |
| Mallinckrodt Hospital Products INC. | $198.00 | 2022-2023 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.68 | 2023-2024 | Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $128.31 | 2021-2025 | Orencia, Sotyktu |
| Lilly USA, LLC | $112.87 | 2022 | |
| Ani Pharmaceuticals, INC. | $107.28 | 2023 | Purified Cortrophin Gel |
| Organon LLC | $99.70 | 2021-2025 | Renflexis, Hadlima |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pbg Puerto Rico LLC | $97.15 | 2020-2023 | |
| Genzyme Corporation | $65.06 | 2023-2024 | |
| Genentech USA, INC. | $25.00 | 2025 | Gazyva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paloma Alejandro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.